MT293 (TRC093) is a recombinant humanized IgG1 monoclonal antibody that inhibits angiogenesis, tumor cell growth and metastasis by binding cleaved collagen, which is predominantly produced in the extracellular matrix of tumors. Micromet’s licensee Tracon Pharmaceuticals began dosing MT293 in a phase 1 trial of cancer patients in July 2007.